Agora Open Science Trust Announces Nomination of M4K2009 as Lead Development Candidate for Pediatric Brain Cancer Therapy
Agora Open Science Trust today announced the nomination of M4K2009 as the lead development candidate for its M4K Pharma program, which applies open science to drive the development of an affordable treatment for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer. Nominating a lead development candidate marks the point where a discovery program selects a single molecule with the highest potential to advance further towards human clinical trials. The selection of M4K2009 represents a significant scientific and organizational milestone.
